Login to Your Account



Potential Cephalon Bid Won't Endanger $1.8B Mesoblast Deal

By Nuala Moran


Wednesday, April 6, 2011
LONDON – Just four months after setting regenerative medicine alive with the first big ticket deal in the field, Mesoblast Ltd. has been forced to reassure shareholders it is immune to any change of strategic direction arising from Valeant Pharmaceuticals International Inc.'s unsolicited offer for Mesoblast's partner, Cephalon Inc. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription